期刊文献+

诱导化疗中期加用柔红霉素对原始细胞比例较高成人Ph-急性淋巴细胞白血病患者一个疗程缓解率的影响 被引量:1

Improved 4-week complete remission rate by additional use of daunorubicin in the medium term of induction chemotherapy in adult Ph-negative acute lymphoblastic leukemia with high proportion of blasts
原文传递
导出
摘要 成人Ph染色体阴性急性淋巴细胞白血病(Ph-ALL)常用的诱导化疗方案是以长春新碱(VDR)或长春地辛(VDS)、蒽环类药物和糖皮质激素(VDP)为基础的方案[1,2]。其中柔红霉素(DNR)的用法为40~45 mg·m-2·d-1×2~3 d,第1、3周,或仅第1周用药,也可每周用药1次。ALL患者获得完全缓解(CR),尤其是诱导化疗1个疗程时获得CR是判断疾病危险度的关键指标之一。
作者 于艺冰 赵婷 王婧 贾劲松 主鸿鹄 江浩 黄晓军 江倩 Yu Yibing;ZhaoTing;Wang Jing;Jia Jinsong;Zhu Honghu;Jiang Hao;Huang Xiaojun;Jiang Qian(Peking University People' s Hospital,Peking University Institute of Hematology,Beijing 100044,China)
出处 《中华血液学杂志》 CAS CSCD 北大核心 2018年第8期676-678,共3页 Chinese Journal of Hematology
  • 相关文献

参考文献7

二级参考文献101

  • 1Anthony H, Goldstore, Susan M, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL trial ( MRC UKALL XII/ECOG E2993 ) . Blood ,2008 ; ( 111 ) : 1827 - 1833.
  • 2Huguet F, Leguay T, Buzyn A, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol, 2009;(27) :911 -918.
  • 3Brnggemann M, Raft T, Flohr T, et al. Clinical significance of mini- mal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood ,2006 ; ( 107 ) : 1116 - 1123.
  • 4Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal re- sidual disease (MRD) in aduh acute lymphoblastic leukemia (ALL). Blood ,2009 ; ( 113 ) :4153 -4162.
  • 5Moorman AV, Chihon L, Bown N,et al. A population-based cytoge- netic study of adults with acute lymphoblastic leukemia. Blood ,2010; 115(2) :206 -214.
  • 6Drexler HG, Thiel E. Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Leukemia, 1991 ;5(8) :637 -645.
  • 7Unal S, Cetin M. The prognostic impact of myeloid antigen expres- sion in pediatric acute lymphoblastic leukemia patients. Turk J Pedi- atr,2008 ;50(6) :533 -536.
  • 8Pui CH, Mullighan CG, Evans WE, et al. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. Blood, 2012, 120(6) :1165 - 1174.
  • 9M6ricke A, Lauten M, Beier R, et al. Prediction of outcome by early response in childhood acute lymphoblastic leukemia. Klin Padiatr, 2013, 225 Suppl 1 :S50-6.
  • 10Gao C, Zhao XX, Li WJ, et al. Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients. Am J Hematol, 2012, 87 ( 11 ) : 1022 - 1027.

共引文献335

同被引文献11

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部